Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes

Leukemia

Volumn 10, Issue 6, 1996, Pages 925-931

  Lotem, J ^a   Sachs, L ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Apoptosis; bcl 2 family; c myc; Cancer therapy; Hematopoietic cytokines; Myeloid cells; p53

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3; MITOMYCIN C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETINOIC ACID; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HUMAN; LEUKEMIA; LEUKEMIA CELL; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030057331     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Arends MJ, Wyllie AH. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 1991; 32: 223-254.
2. Sachs L. The molecular control of blood cell development. Science 1987; 238: 1374-1379.
3. Sachs L. The control of growth and differentiation in normal and leukemic blood cells. The 1989 Alfred P Sloan Prize of the General Motors Research Foundation. Cancer 1990; 65: 2196-2206.
4. Sachs L. The molecular control of hematopoiesis: from clonal development in culture to therapy in the clinic. Int J Cell Cloning 1992; 10: 196-204.
5. Sachs L. The molecular control of hemopoiesis and leukemia. CR Acad Sci Paris, Sciences de la vie 1993; 316: 882-891.
6. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993; 82: 15-21.
7. Sachs L, Lotem J. Apoptosis in the haemopoietic system. In: Gregory CD (ed). Apoptosis and the Immune Response. John Wiley and Sons: New York, 1995, pp 371-403.
8. + myeloid leukemic cells. J Cell Physiol 1977; 92: 97-108.
9. Lotem J, Cragoe EJ Jr, Sachs L. Rescue from programmed cell death in leukemic and normal myeloid cells. Blood 1991; 78: 953-960.
10. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76-79.
11. Duke RC, Cohen JJ. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Res 1986; 5: 289-299.
12. Ihle JN, Askew D. Origins and properties of hematopoietic growth-factor-dependent cell lines. Int J Cell Cloning 1989; 7: 68-91.
13. Kato J, Sherr CJ. Human colony-stimulating factor 1 (CSF-1) receptor confers CSF-1 responsiveness to interleukin-3-dependent 32D C13 mouse myeloid cells and abrogates differentiation in response to granulocyte CSF. Blood 1990; 75: 1780-1787.
14. Rodriguez-Tarduchy G, Collins M, López-Rivas A. Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin 3 and calcium ionophores. EMBO J 1990; 9: 2997-3002.
15. Lotem J, Sachs L. Interferon-γ inhibits apoptosis induced by wild-type p53, cytotoxic anti-cancer agents and viability factor deprivation in myeloid cells. Leukemia 1995; 9: 685-692.
16. Rodriguez-Tarduchy G, Collins MK, Garcia I, López-Rivas A. Insulin-like growth factor-1 inhibits apoptosis in IL-3 dependent hemopoietic cells. J Immunol 1992; 149: 535-540.
17. Kannan Y, Ushio H, Koyama H, Okada M, Oikawa M, Yoshihara T, Kaneko M, Matsuda H. 2.5S nerve growth factor enhances survival, phagocytosis, and Superoxide production of murine neutrophils. Blood 1991; 77; 1320-1325.
18. McConkey DJ, Orrenius S, Jondal M. Cellular signalling in programmed cell death (apoptosis). Immunol Today 1990; 11: 120-121.
19. Rodriguez-Tarduchy G, López-Rivas A. Phorbol esters inhibit apoptosis in IL-2 dependent T lymphocytes. Biochem Biophys Res Commun 1989; 164: 1069-1075.
20. + antiporter in suppression of apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin-3. J Biol Chem 1992; 267: 9980-9987.
21. Lotem J, Sachs L. Regulation of normal differentiation in mouse and human myeloid leukemic cells by phorbol esters and the mechanism of tumor promotion. Proc Natl Acad Sci USA 1979; 76: 5158-5162.
22. Lotem J, Sachs L. Regulation of growth and differentiation by phorbol esters and the mechanism of tumor promotion. In: Hecker E, Fusenig NE, Kunz W, Marks F, Thielman HW (eds). Carcinogenesis, Vol 7. Cocarcinogenesis and Biological effects of tumor promoters. New York: Raven Press, 1982, pp 385-390.
23. Cook WD, Metcalf D, Nicola N, Burgess AW, Walker F. Malignant transformation of a growth factor-dependent myeloid cell line by Abelson virus without evidence of an autocrine mechanism. Cell 1985; 41: 677-683.
24. Pierce JH, Di Fiore PP, Aaronson SA, Potter M, Pumphrey J, Scott A, Ihle JN. Neoplastic transformation of mast cells by Abelson-Mu-LV: abrogation of IL-3 dependence by a nonautocrine mechanism. Cell 1985; 41: 685-693.
25. Owen PJ, Musk P, Evans CA, Whetton AD. Cellular signalling events elicited by v-abl associated with growth factor independence in an interleukin-3-dependent cell line. J Biol Chem 1993; 268: 15696-15703.
26. Laneuville P, Heisterkamp N, Groffen J. Expression of the chronic myelogenous leukemia-associated p210 bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene 1991; 6: 275-282.
27. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
28. Griffin JD, Löwenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986; 68: 1185-1195.
29. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332: 83-85.
30. Vink A, Coulie P, Warnier G, Renauld J-C, Stevens M, Doukers D, Van Snick J. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 and its receptor. J Exp Med 1990; 172: 997-1000.
31. Klein B, Wijdens J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J, Bataille R. Murine anti-interleukin 6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198-1204.
32. Fibach E, Sachs L. Control of normal differentiation of myeloid leukemic cells. XI. Induction of a specific requirement for cell viability and growth during differentiation of myeloid leukemic cells. J Cell Physiol 1976; 89: 259-266.
33. Lotem J, Sachs L. Mechanisms that uncouple growth and ditferentiation in myeloid leukemia cells. Restoration of requirement for normal growth inducing protein without restoring induction of differentiation inducing protein. Proc Natl Acad Sci USA 1982; 79: 4347-4351.
34. Lotem J, Sachs L. Coupling of growth and differentiation in normal myeloid precursors and the breakdown of this coupling in leukemia. Int J Cancer 1983; 32: 127-134.
35. Lotem J, Sachs L. Induction of dependence on hematopoietic proteins for viability and receptor upregulation in differentiating myeloid leukemic cells. Blood 1989; 74: 579-585.
36. Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukemia. Nature 1978; 274: 535-539.
37. Lotem J, Sachs L. In vivo induction of normal differentiation in myeloid leukemic cells. Proc Natl Acad Sci USA 1978; 75: 3781-3785.
38. Lotem J, Sachs L. In vivo control of differentiation of myeloid leukemic cells by recombinant granulocyte-macrophage colony-stimulating factor and interleukin 3. Blood 1988; 71: 375-382.
39. Lotem J, Sachs L. In vivo inhibition of the development of myeloid leukemia by injection of macrophage and granulocyle inducing protein. Int J Cancer 1981; 28: 375-386.
40. Lotem J, Sachs L. Control of in vivo differentiation of myeloid leukemic cells. IV. Inhibition of leukemia development by myeloid differentiation inducing protein. Int J Cancer 1984; 33: 147-154.
41. Degos L. Differentiation therapy and leukemia. Leukemia 1993; 7: 766-772.
42. Ottman OG, Pelus LM. Differential proliferative effects of transforming growth factor β on human hematopoietic progenitor cells. J Immunol 1988; 140: 2661-2665.
43. Sing GK, Keller JR, Ellingsworth LR, Ruscetti FW. Transforming growth factor β selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood 1988; 72: 1504-1511.
44. Hampson J, Ponting ILO, Cook N, Vodinelich L, Redmond S, Roberts AB, Dexter TM. The effects of TGF-β on haemopoietic cells. Growth Factors 1989; 1: 193-202.
45. Cashman JD, Eaves AC, Raines EW, Ross R, Eaves C. Mechanisms that regulate cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulating role of a variety of mesenchymal cell activators and inhibitory effect of TGF-β. Blood 1990; 75: 96-101.
46. Lotem J, Sachs L. Selective regulation of the activity of different hematopoietic regulatory proteins by transforming growth factor β1 in normal and leukemic myeloid cells. Blood 1990; 76: 1315-1322.
47. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth-factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750-1757.
48. Lin J-K, Chou C-K. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor β1. Cancer Res 1992; 52: 385-388.
49. Yanagihara K, Tsumuraya M. Transforming growth factor β1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 1992; 52: 4042-4045.
50. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 1991; 352: 345-347.
51. Kerr JFR, Harmon BV. Definition and incidence of apoptosis: an historical perspective. In: Tomei LD, Cope FO (eds). Current Communications in Cell and Molecular Biology, vol. 3. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1991, pp 5-29.
52. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
53. Kaplinsky C, Lotem J, Sachs L. Protection of human myeloid leukemic cells against doxorubicin induced apoptosis by granulocyte-macrophage colony stimulating factor and interleukin 3. Leukemia 1996; 10: 460-465.
54. Rosselli F, Sanceau J, Wietzerbin J, Moustacchi E. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi Anemia. I. Involvement of interleukin 6. Hum Genet 1992; 89: 42-48.
55. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J. Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood 1994; 84: 3063-3070.
56. McConkey DJ, Hartzell P, Chow SC, Orrenius S, Jondal M. Interleukin 1 inhibits T cell receptor-mediated apoptosis in immature thymocytes. J Biol Chem 1990; 265: 3009-3011.
57. Groux H, Monte D, Plouvier B, Capron A, Ameisen J. CD3-mediated apoptosis of human medullary thymocytes and activated T cells: respective roles of interleukin 1, interleukin 2, interferon γ and accessory cells. Eur J Immunol 1993; 23: 1623-1629.
58. Migliorati G, Nicoletti I, Pagliacci MC, D'Amio L, Riccardi C. Interleukin 4 protects double-negative and CD4 single-positive thymocytes from dexamethasone-induced apoptosis. Blood 1993; 81: 1352-1358.
59. Walker PR, Kwast-Welfeld J, Gourdeau H, Leblanc J, Neugebauer W, Sikorska M. Relationship between apoptosis and the cell cycle in lymphocytes: roles of protein kinase C, tyrosine phosphorylation, and AP-1. Exp Cell Res 1993; 207: 142-151.
60. Zubiaga AM, Munoz E, Huber BT. IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis. J Immunol 1992; 149: 107-112.
61. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319-1326.
62. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-2808.
63. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-1332.
64. Lotem J, Sachs L. Selective regulation by hydrocortisone of induction of in vivo differentiation of myeloid leukemia cells with granulocyte-macrophage colony-stimulating factor, interleukin 6 and interleukin 1α. Leukemia 1992; 6: 426-431.
65. Kunicka JE, Talle MA, Denhardt GH, Brown M, Prince LA, Goldstein G. Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol 1993; 149: 39-49.
66. Lotem J, Sachs L. Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and defective myeloid leukemic cells. Cell Growth Differ 1993; 4: 41-47.
67. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemic cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
68. Chomienne C, Barbey S, Balitrand N, Degos L, Sachs L. Regulation of bcl-2 and cell death by all-frans retinoic acid in acute promyelocytic cells. Proc Am Assoc Cancer Res 1992; 33: 41.
69. Lotem J, Sachs L. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways. Cell Growth Differ 1994; 5: 321-327.
70. Reed JC, Cuddy M, Haldar S, Croce C, Nowel C, Makover D, Bradley K. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc Natl Acad Sci USA 1990; 87: 3660-3664.
71. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F, Bordessoule D, Sadoun A, Tiberghien P, Fegueaux N, Daniel MT, Chomienne C, Degos L. All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176-2181.
72. Lotem J, Sachs L. Regulation of bcl-2, bcl-X and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 1995; 6: 647-653.
73. Boise LH, González-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson GB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
74. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. Mcl 1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc Natl Acad Sci USA 1993; 90: 3516-3520.
75. Lin EY, Orlofsky A, Berger MS, Prystowsky MB. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2.1 Immunol 1993; 151: 1979-1988.
76. Oltvai Z, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
77. L and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.
78. Farrow SN, White JHM, Martinou I, Raven T, Pun K-T, Grinham CJ, Martinou J-C, Brown R. Cloning of a bcl-2 homologue by interaction with adenovirus E1B19K. Nature 1995; 374: 731-733.
79. Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995; 374: 733-736.
80. Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Umansky SR, Tomei LD, Barr PJ. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995; 374: 736-739.
81. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ, Chinnadurai G. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival promoting proteins. Oncogene 1995; 11: 1921-1928.
82. Kumar S. ICE-like proteases in apoptosis. Trends Biochem Sci 1995; 20: 198-202.
83. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
84. Oren M. p53: the ultimate tumor suppressor gene? FASEB J 1992; 6: 3169-3176.
85. Ehinger M, Nilsson E, Persson A-M, Olsson I, Gullberg U. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. Cell Growth Differ 1995; 6: 9-17.
86. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild type p53 in a human colon tumor derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-4499.
87. Ryan JJ, Danish R, Goltlieb CA, Clarke MF. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 1993; 13: 711-719.
88. Wang Y, Ramqvist T, Szekely L, Axelson H, Klein G, Wiman GC. Reconstitution of wild-type p53 expression triggered apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Differ 1993; 4: 467-473.
89. Ramqvist T, Magnusson KP, Wang Y, Szekely L, Klein G, Wiman KG. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 1993; 8: 1495-1500.
90. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence J, May P, Oren M. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 1993; 13: 1415-1423.
91. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993; 82: 1092-1096.
92. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
93. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852.
94. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994; 79: 329-339.
95. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 1985; 82: 790-794.
96. Ragimov N, Krauskopt A, Navot N, Rotter V, Oren M, Aloni Y. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 1993; 8: 1183-1193.
97. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991; 88: 7605-7609.
98. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Develop 1995; 9: 2170-2183.
99. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
100. Harper JW, Adami CR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
101. cip/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
102. Brugarolas J, Chandrasekaran C, Cordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552-557.
103. Johnson P, Chung S, Benchimol S. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol 1993; 13: 1456-1463.
104. Kelly LL, Green WF, Hicks GG, Bondurant MC, Koury MJ, Ruley HE. Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol Cell Biol 1994; 14: 4183-4192.
105. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915-1922.
106. Harrington E, Fanidi A, Bennett M, Evan G. Modulation of Myc-induced apoptosis by specific cytokines. EMBO J 1994; 13: 3286-3295.
107. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
108. Bissonnette RP, Echeverri F, Mahboudi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-554.
109. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359: 554-556.
110. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
111. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-333.
112. Lotem J, Sachs L. A mutant p53 antagonizes the deregulated c-myc mediated enhancement of apoptosis and decrease in leukemogenicity. Proc Natl Acad Sci USA 1995; 92: 9672-9676.
113. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 5742-5746.
114. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Develop 1993; 7: 546-554.
115. Yanai N, Obinata M. Apoptosis is induced at nonpermissive temperature by a transient increase in p53 in cell lines immortalized with temperature-sensitive SV40 large T-antigen gene. Exp Cell Res 1994; 211: 296-300.
116. Pan H, Griep AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Develop 1994; 8: 1285-1299.
117. Oca Luna RC, Wagner DS, Lozano C. Rescue of early embryonic lethality in mdm-2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
118. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
119. Lee EYP, Chang C-Y, Hu N, Wang Y-CJ, Lai C-C, Herrup K, Lee W-H, Bradley A. Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoiesis. Nature 1992; 359: 288-294.
120. Clarke AR, Maandag ER, Van Roon M, Van der Lugt NMT, Van der Valk M, Hooper ML, Berns A, Te Riele H. Requirement for a functional Rb-1 gene in murine development. Nature 1992; 359: 328-330.
121. Morgenbesser SD, Williams BO, Jacks T, De Pinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994; 371: 72-74.
122. Haupt Y, Rowan S, Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRb. Oncogene 1995; 10: 1563-1571.
123. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang A, Fung Y-KT, Israel MA. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995; 14: 461-472.
124. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Develop 1995; 9: 2143-2156.
125. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr. Mice deficient in p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
126. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989; 9: 3982-3991.
127. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Cryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1233-1238.
128. Strivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
129. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53: 4129-4133.
130. Clayman GL, El-Naggar AK, Roth JA, Zhang W-W, Goepfert H, Taylor DL, Liu T-J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
131. S adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci USA 1995; 92: 11024-11028.